Feeds:
Posts
Comments

Archive for the ‘LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management’ Category


Live Notes, Real Time Conference Coverage 2020 AACR Virtual Meeting April 28, 2020 Symposium: New Drugs on the Horizon Part 3 12:30-1:25 PM

Reporter: Stephen J. Williams, PhD

New Drugs on the Horizon: Part 3
Introduction

Andrew J. Phillips, C4 Therapeutics

  • symposium brought by AACR CICR and had about 30 proposals for talks and chose three talks
  • unfortunately the networking event is not possible but hope to see you soon in good health

ABBV-184: A novel survivin specific T cell receptor/CD3 bispecific therapeutic that targets both solid tumor and hematological malignancies

Edward B Reilly
AbbVie Inc. @abbvie

  • T-cell receptors (TCR) can recognize the intracellular targets whereas antibodies only recognize the 25% of potential extracellular targets
  • survivin is expressed in multiple cancers and correlates with poor survival and prognosis
  • CD3 bispecific TCR to survivn (Ab to CD3 on T- cells and TCR to survivin on cancer cells presented in MHC Class A3)
  • ABBV184  effective in vivo in lung cancer models as single agent;
  • in humanized mouse tumor models CD3/survivin bispecific can recruit T cells into solid tumors; multiple immune cells CD4 and CD8 positive T cells were found to infiltrate into tumor
  • therapeutic window as measured by cytokine release assays in tumor vs. normal cells very wide (>25 fold)
  • ABBV184 does not bind platelets and has good in vivo safety profile
  • First- in human dose determination trial: used in vitro cancer cell assays to determine 1st human dose
  • looking at AML and lung cancer indications
  • phase 1 trial is underway for safety and efficacy and determine phase 2 dose
  • survivin has very few mutations so they are not worried about a changing epitope of their target TCR peptide of choice

The discovery of TNO155: A first in class SHP2 inhibitor

Matthew J. LaMarche
Novartis @Novartis

  • SHP2 is an intracellular phosphatase that is upstream of MEK ERK pathway; has an SH2 domain and PTP domain
  • knockdown of SHP2 inhibits tumor growth and colony formation in soft agar
  • 55 TKIs there are very little phosphatase inhibitors; difficult to target the active catalytic site; inhibitors can be oxidized at the active site; so they tried to target the two domains and developed an allosteric inhibitor at binding site where three domains come together and stabilize it
  • they produced a number of chemical scaffolds that would bind and stabilize this allosteric site
  • block the redox reaction by blocking the cysteine in the binding site
  • lead compound had phototoxicity; used SAR analysis to improve affinity and reduce phototox effects
  • was very difficult to balance efficacy, binding properties, and tox by adjusting stuctures
  • TNO155 is their lead into trials
  • SHP2 expressed in T cells and they find good combo with I/O with uptick of CD8 cells
  • TNO155 is very selective no SHP1 inhibition; SHP2 can autoinhibit itself when three domains come together and stabilize; no cross reactivity with other phosphatases
  • they screened 1.5 million compounds and got low hit rate so that is why they needed to chemically engineer and improve on the classes they found as near hits

Closing Remarks

 

Xiaojing Wang
Genentech, Inc. @genentech

Follow on Twitter at:

@pharma_BI

@AACR

@CureCancerNow

@pharmanews

@BiotechWorld

@HopkinsMedicine

#AACR20

Read Full Post »


Asset

Classes

Type

Quantity Business Model Asset Protection

Transaction Type

 

Asset Class I

 

 

 

The Journal 3/3/2020 Views 1,723,051

5,742 articles on 3/3/2020

 

 

Valuation [$40M] done by Joel on Alex WP Data

 

Revenue Potential: Partnership Programs – Subscription/Access fee Legal and Pharma, free for Academia

 

 

 

Copyright Law

 

 

 

B2B & B2B & B2C

 

 

Asset Class II

BioMed e-Series https://pharmaceuticalint elligence.com/2019- vista/global-market- penetration-forecast-for- each-volume-in-the-16- volume-biomed-e- series/  

 

16 volumes

 

Valuation [$5M] done by Joel & Aviva

 

 

Revenue Potential: Partnership Programs – Subscription/Access fee Legal and Pharma, free for Academia

 

 

 

Copyright Law

 

 

 

B2B & B2B & B2C

 

 

 

Asset Class III

 

eProceedings https://pharmaceuticalint elligence.com/2019- vista/e-proceedings-and- tweet-collections-per- conference-2013-2020- viewsdownloads-x-100- real-time-coverage-of- 60-events-by-ala-sjw/

 

60 events Valuation [$1.4M]

done by Dr. Williams &

Aviva

 

 

 

Revenue Potential: Partnership Programs – Subscription/Access fee Legal and Pharma, free for Academia

 

 

 

 

Copyright Law

 

 

 

 

B2B & B2B & B2C

 

 

Asset Class IV

 

 

Platform, composition of methods and workflows for the content creation of scientific curations

 

 

 

TBD

Customized Platform Infrastructure, Building Tools for new products, venturing to new Disciplines beyond HealthCare,knowhow contracts in new geographies  

 

Copyright Law and Proprietary Knowhow

 

 

 

internal and contracts

Asset

Classes

Type Quantity Business Model Asset Protection

Transaction Type

 

Asset Class V

 

 

Gallery of Biological Images in use in Articles and Books

 

 

 

TBD

 

 

Artifacts in the of Content Creation of PRIOR ART

Copyright upon EMBEDDED

in original curations

Internal Use – subsets per BioMed e- Series in Medical Specialties
 

 

Asset Class VI

 

 

 

Team of Experts

 

 

BIOs Final Improvement Team (FIT)

 

 

 

Factor of Content Creation

Personal Agreement s to become Employment     Contracts Post-Exit  

 

 

Internal

 

Asset Class VII

 

 

Royalties on BioMed e- Series:Page downloads, Book borrowings and Book sale

 

 

111,645 page downloads in total on 3/9/2020

 

 

 

Current Account Receivables

 

 

Royalties Agreement with KDP

@Amazon

Derivative of Interest in Content (120,000

Pages download in 16 books

 

Asset Class VIII

 

 

Subscribers to the Website

 

 

2,554 on 3/29/2020

 

 

Potential Account Receivables

 

 

n/a

 

Drivers of Loyalty & Success

 

Asset Class IX

 

INTANGIBLE ASSETS

& Intrinsic Value = Good Will

 

 

TBD

 

 

Potential Account Receivables

 

 

Copyright Law

 

 

External

e-Reputation

Asset Class X  

e-VOICE PODCASTS

Audio Library

 

TBD

 

Potential Account Receivables

 

Copyright Law

 

B2B & B2B & B2C

Asset

Classes

Type Quantity Business Model Asset Protection Transaction Type

 

Asset Classes

Unique Value Proposition Key Paying Customers Key Stakeholders

Unique Selling Point

 

 

 

Asset Class I

 

We create a new level of knowledge that is current and lively on the current issues and based on a discussion of multiple KOL

 

Legal, regulatory, Pharma R&D, Non academia, Gov, Journalists, media, Premium audience

 

 

academics, students, science addicts

 

 

Current high level accessible knowledge

 

 

 

Asset Class II

 

in depth as of day of publication knowledge collection of topic, background, good as a course or a journal club guide. State of the art, science based, outcome oriented KOL based perspective.

 

Legal, regulatory, pharma R&D, non academia, Gov, journalists and media, premium audience

 

Universities, Patient advocacy groups, Professional associations, Curriculum developers

 

current highly multiple domain specialized accessible knowledge

 

 

 

 

Asset Class III

 

 

In depth on publication day, knowledge collection of topic, depicts event spirit and highlights with KOL perspective and annotation, scientific documents and historical state of Science

 

 

Global Biotech & Healthcare Conference Organizers + Customers of Asset Class I+II

 

 

Conference Participants, Future Attendees & Participants Missing Conference Sessions

 

 

 

Real time, On demand, Event Tweet Collections

 

 

 

Asset Class IV

platform that allow harnessing the state of knowledge to produce a state of the art coverage of eventual or topic based current knowledge products to a specific targeted audience  

New topics, new geographies knowledge community makers, LPBI new products pipeline

 

the global KOL community in health, life- sciences and pharma

 

 

unique, easy, proven, state of the art

Transaction Type Unique Value Proposition Key Paying Customers Key Stakeholders Unique Selling Point
Asset Class V  

 

Selection done by Domain Experts for IP creation of original content

 

 

 

TBD

 

e-Readers, Publishers, Future Publishing Academics

 
 

 

 

Asset Class VI

 

 

Group of outcome-oriented KOLs in Health Care & Pharma Industry & Academia expertise

 

 

 

Human Capital asset

   
Asset Class VII  

 

 

Global reach

 

 

 

e-Readers of Science e-Books

 

 

Scientist- contributors on FIT and Past contributors

 
Asset Class VIII  

A reach into the top of the line Executives and KOLs in Pharma and Life sciences R&D

 

To be segmented and Targeted for Outreach and Outbound Marketing

 

 

Venture Owner

Top of the line, majority of the Global market leaders in Biotech
 

 

Asset Class IX

 

 

Product/Service Quality & Reputation

 

 

Acquirer and Its Customers

VERACITY SEEKERS and EVIDENCE BASED MEDICINE PROMOTERS  
 

Asset Class X

 

Selection of most prominent Figures to be featured

 

Media Licensing Agreements

 

PBS, TV

Networks

 
Transaction Type Unique Value Proposition Key Paying Customers Key Stakeholders Unique Selling Point

Read Full Post »


Is It Time for the Virtual Scientific Conference?: Coronavirus, Travel Restrictions, Conferences Cancelled

Curator: Stephen J. Williams, PhD.

UPDATED 3/12/2020

To many of us scientists, presenting and attending scientific meetings, especially international scientific conferences, are a crucial tool for disseminating and learning new trends and cutting edge findings occurring in our respective fields.  Large international meetings, like cancer focused meetings like AACR (held in the spring time), AAAS and ASCO not only highlight the past years great discoveries but are usually the first place where breakthroughs are made known to the scientific/medical community as well as the public.  In addition these conferences allow for scientists to learn some of the newest technologies crucial for their work in vendor exhibitions.

During the coronavirus pandemic, multiple cancellations of business travel, conferences, and even university based study abroad programs are being cancelled and these cancellations are now hitting the 2020 Spring and potentially summer scientific/medical conferences.  Indeed one such conference hosted by Amgen in Massachusetts was determined as an event where some attendees tested positive for the virus, and as such, now other attendees are being asked to self quarantine.

Today I received two emails on conference cancellations, one from Experimental Biology in California and another from The Cancer Letter, highlighting other conferences, including National Cancer Coalition Network (NCCN) meetings which had been canceled.

 

Experimental Biology - San Diego 2020 - April 4-7

Dear Stephen,

After thoughtful deliberations, the leaders of the Experimental Biology host societies have made the difficult but necessary decision to cancel Experimental Biology (EB) 2020 set to take place April 4–7 in San Diego, California. We know how much EB means to everyone, and we did not make this decision in haste. The health and safety of our members, attendees, their students, our staff, partners and our communities are our top priority.

As we have previously communicated via email, on experimentalbiology.org and elsewhere, EB leadership has been closely monitoring the spread of COVID-19 (coronavirus disease). Based on the latest guidance from public health officials, the travel bans implemented by different institutions and the state of emergency declared in California less than 48 hours ago, it became clear to us that canceling was the right course of action.

We thank you and the entire EB community for understanding the extreme difficulty of this decision and for your commitment to the success of this conference – from the thousands of attendees to the presenters, exhibitors and sponsors who shared their time, expertise, collaboration and leadership. We deeply appreciate your contributions to this community.

What Happens Next?

Everyone who has registered to attend the meeting will receive a full registration refund within the next 45 days. Once your registration cancellation is processed, you will receive confirmation in a separate email. You do not need to contact anyone at EB or your host society to initiate the process. Despite the cancellation of the meeting, we are pleased to tell you that we will publish abstracts in the April 2020 issue of The FASEB Journal as originally planned. Please remember to cancel any personal arrangements you’ve made, such as travel and housing reservations. 

We ask for patience as we evaluate our next steps, and we will alert you as additional information becomes available please see our FAQs for details.

And in The Cancer Letter

Coronavirus vs. oncology: Meeting cancellations, travel restrictions, fears about drug supply chain

By Alexandria Carolan

NOTE: An earlier version of this story was published March 4 on the web and was updated March 6 to include information about restricted travel for employees of cancer centers, meeting cancellations, potential disruptions to the drug supply chain, and funds allocated by U.S. Congress for combating the coronavirus.

Further updates will be posted as the story develops.

Forecasts of the inevitable spread of coronavirus can be difficult to ignore, especially at a time when many of us are making travel plans for this spring’s big cancer meetings.

The decision was made all the more difficult earlier this week, as cancer centers and at least one biotechnology company—Amgen—implemented travel bans that are expected to last through the end of March and beyond. The Cancer Letter was able to confirm such travel bans at Fred Hutchinson Cancer Research Center, MD Anderson Cancer Center, and Dana-Farber Cancer Institute.

Meetings are getting cancelled in all fields, including oncology:

The National Comprehensive Cancer Network March 5 postponed its 2020 annual conference of about 1,500 attendees March 19-22 in Orlando, citing precautions against coronavirus.

“The health and safety of our attendees and the patients they take care of is our number one concern,” said Robert W. Carlson, chief executive officer of NCCN. “This was an incredibly difficult and disappointing decision to have to make. However, our conference attendees work to save the lives of immunocompromised people every day. Some of them are cancer survivors themselves, particularly at our patient advocacy pavilion. It’s our responsibility, in an abundance of caution, to safeguard them from any potential exposure to COVID-19.”

UPDATED 3/12/2020

And today the AACR canceled its yearly 2020 Meeting (https://www.aacr.org/meeting/aacr-annual-meeting-2020/coronavirus-information/)

The American Association for Cancer Research (AACR) Board of Directors has made the difficult decision, after careful consideration and comprehensive evaluation of currently available information related to the novel coronavirus (COVID-19) outbreak, to terminate the AACR Annual Meeting 2020, originally scheduled for April 24-29 in San Diego, California. A rescheduled meeting is being planned for later this year.

The AACR has been closely monitoring the rapidly increasing domestic and worldwide developments during the last several weeks related to COVID-19. This evidence-based decision was made after a thorough review and discussion of all factors impacting the Annual Meeting, including the U.S. government’s enforcement of restrictions on international travelers to enter the U.S.; the imposition of travel restrictions issued by U.S. government agencies, cancer centers, academic institutions, and pharmaceutical and biotech companies; and the counsel of infectious disease experts. It is clear that all of these elements significantly affect the ability of delegates, speakers, presenters of proffered papers, and exhibitors to participate fully in the Annual Meeting.

The health, safety, and security of all Annual Meeting attendees and the patients and communities they serve are the AACR’s highest priorities. While we believe that the decision to postpone the meeting is absolutely the correct one to safeguard our meeting participants from further potential exposure to the coronavirus, we also understand that this is a disappointing one for our stakeholders. There had been a great deal of excitement about the meeting, which was expected to be the largest ever AACR Annual Meeting, with more than 7,400 proffered papers, a projected total of 24,000 delegates from 80 countries and more than 500 exhibitors. We recognize that the presentation of new data, exchange of information, and opportunities for collaboration offered by the AACR Annual Meeting are highly valued by the entire cancer research community, and we are investigating options for rescheduling the Annual Meeting in the near future.

We thank all of our stakeholders for their patience and support at this time. Additional information regarding hotel reservation cancellations, registration refunds, and meeting logistics is available on the FAQ page on the AACR website. We will announce the dates and location of the rescheduled AACR Annual Meeting 2020 as soon as they are confirmed. Our heartfelt sympathies go out to everyone impacted by this global health crisis.

However,  according to both Dr. Fauci and Dr. Scott Gottlieb (former FDA director)  the outbreak may revisit the US and the world in the fall (see https://www.cnbc.com/2020/03/04/were-losing-valuable-time-ex-fda-chief-says-of-coronavirus-spread.html)  therefore these meetings may be cancelled for the whole year.

Is It Time For the Virtual (Real-Time) Conference?

Readers of this Online Access Journal are familiar with our ongoing commitment to open science and believe that forming networks of scientific experts in various fields using a social strategy is pertinent to enhancing the speed, reproducibility and novelty of important future scientific/medical discoveries.  Some of these ideas are highlighted in the following articles found on this site:

Scientific Curation Fostering Expert Networks and Open Innovation: Lessons from Clive Thompson and others

Old Industrial Revolution Paradigm of Education Needs to End: How Scientific Curation Can Transform Education

Twitter is Becoming a Powerful Tool in Science and Medicine

e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point

Reconstructed Science Communication for Open Access Online Scientific Curation

In addition, we understand the importance of communicating the latest scientific/medical discoveries in an open and rapid format, accessible over the social media platforms.  To this effect we have developed a methodology for real time conference coverage

see  Press and Conference Coverage

at  https://pharmaceuticalintelligence.com/press-coverage/

AND

The Process of Real Time Coverage using Social Media

at https://pharmaceuticalintelligence.com/press-coverage/part-one-the-process-of-real-time-coverage-using-social-media/

Using these strategies we are able to communicate, in real time, analysis of conference coverage for a multitude of conferences.

Has technology and social media platforms now have enabled our ability to rapidly communicate, in a more open access platform, seminal discoveries and are scientists today amenable to virtual type of meetings including displaying abstracts using a real-time online platform?

Some of the Twitter analytics we have curated from such meetings show that conference attendees are rapidly adopting such social platforms to communicate with their peers and colleagues meeting notes.

Statistical Analysis of Tweet Feeds from the 14th ANNUAL BIOTECH IN EUROPE FORUM For Global Partnering & Investment 9/30 – 10/1/2014 • Congress Center Basel – SACHS Associates, London

Word Associations of Twitter Discussions for 10th Annual Personalized Medicine Conference at the Harvard Medical School, November 12-13, 2014

Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950

Twitter Analytics on the Inside 3DPrinting Conference #I3DPConf

 

Other Twitter analyses of Conferences Covered by LPBI in Real Time have produced a similar conclusion: That conference attendees are very engaged over social media networks to discuss, share, and gain new insights into material presented at these conferences, especially international conferences.

And although attracting international conferences is lucrative to many cities, the loss in revenue to organizations, as well as the loss of intellectual capital is indeed equally as great.  

Maybe there is room for such type of conferences in the future, and attending by a vast more audience than currently capable. And perhaps the #openscience movement like @MozillaScience can collaborate with hackathons to produce the platforms for such an online movement of scientific conferences as a Plan B.

Other articles on Real Time Conference Coverage in the Online Open Access Journal Include:

Innovations in electronic Scientific Publishing (eSP): Case Studies in Marketing eContent, Curation Methodology, Categories of Research Functions, Interdisciplinary conceptual innovations by Cross Section of Categories, Exposure to Frontiers of Science by Real Time Press coverage of Scientific Conferences

Real Time Coverage and eProceedings of Presentations on 11/16 – 11/17, 2016, The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Tweets by @pharma_BI and by @AVIVA1950: Real Time Coverage and eProceedings of The 11th Annual Personalized Medicine Conference, November 18-19, 2015, Harvard Medical School

REAL TIME Cancer Conference Coverage: A Novel Methodology for Authentic Reporting on Presentations and Discussions launched via Twitter.com @ The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum in Drug Development, 19th March 2014 • New York Academy of Sciences • USA

Search Results for ‘Real Time Conference’

Read Full Post »


Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

Author: Aviva Lev-Ari, PhD, RN

https://feinternational.com/blog/how-do-you-value-an-online-business/

How to Value a Website or Internet Business in 2020

 

From: Thomas Smale <acquisitions@feinternational.com>

Reply-To: <acquisitions@feinternational.com>

Date: Thursday, February 27, 2020 at 4:30 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Your Guide to Buying an Online Business

Hi Aviva

Thanks for your interest in our free Guide to Buying an Online Business. Please click below to download.

Guide-to-Buying-an-Online-Business-vLQ

Guide-to-Buying-an-Online-Business-vHQ

We will be in touch in a few days to see if you have any questions!

Regards,


Thomas Smale
Founder

FE International, Inc.

www.feinternational.com

Follow us on FacebookLinkedIn and Twitter.

 

FE International Framework

Alternative Metrics for Valuing Websites Or Internet Business

  • Discounted Cashflow Analysis
  • Precedent Transactions
  • Earnings-Multiple
  • Traffic Valuation
  • A Multiple-Based Approach to Valuing a Website or Internet Business

Defining Profitability

Factors That Influence The Multiple: Financials, Traffic, Operations, niche, Customer base

Valuation Multiples In Practice

Image source:

https://feinternational.com/blog/how-do-you-value-an-online-business/

Consider the Current Business Model

How to Value a SaaS Business

How to Value an E-Commerce Business

How to Value an App

 

Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

On 2/27/2020 5:30AM – Aviva Wrote:

This is an excellent article.

It is very applicable for

1. Travel Websites

2. eCommerce transaction sites

3. Content: chiefly NEWS

CLAIMER:

Our PharmaceuticalIntellugence.com

A. Is an Internet based Business of Digital Content

B. Unlike 1,2,3 – 

B.1 EVERY CURATION in the Journal

has content with INTRINSIC value in the form of IP belonging to the Curator’s Expertise

B.2 ALL 16 Volumes in the BioMed e-Series represent an ORIGINAL electronic Table of Contents eTOCs designed by a very unique Editor(s).

B.2.1 The evolution of the eTOCs takes many iterations among the editors AND only the Editor-in-Chief after requests for substantial alterations, usually ADD new content, declares “This is the final eTOCs for Series X, Volume Y.

(These alterations AUGMENT the IP embedded in the eTOCs design)

Example: 

Genomics Volume 2: there were three iterations of eTOCs between Prof. Feldman and Aviva, first dated 2016. 

In 2019, 

• Aviva created single handedly the FINAL version of eTOCs and 

• commissioned ALL scientists to populated Parts 7 and 8 with new content not in existence in the Journal. 

• made Part 3: AI in Medicine

• made Part 4: Single Cell Sequencing

• obtained from Part 5: Evolution & Genomics from Prof. Feldman as an original curations WRITTEN for this Volume 

THAT IS INTRINSIC VALUE DERIVED FROM EXPERTISE and it defines the QUALITY of this book, which is not measured by traffic. Advertisement of the book could drive page downloads and book sales. It can be done ANY TIME because each article in the book is updated in perpetuity !! A feature of our BioMed e-Series.

Does the DCF model capture the value of NON-perishable content in our Jornal and Books – no it does not

It will be valued at PREMIUM an acquirer who is sensitive to content obsolescence !!!!!

B.2.2 Page downloading will be updated for 4/19/2020

C. eProceedings are generated by Experts and the TWEET Collections carry the favorable Tweet Analytics that we presented: 

• HIGH engagement, 

• HIGHEST ratio tweet/likes in the Industry

• Ranked 2nd, 3rd, 4th in TOP 10 Influencers at #1 Conference in AI in Medicine in the World, 4/2019

HOW THUS VALUATION article calling for 2 to 4.5 multiplier is to capture LPBI’s

1. ECONOMIC intrinsic value on non perishable content 

2. Top Expertise

3. electronic Reputation and other INTANGIBLE ASSETS as VALUE DRIVERS

FE International’s model has only LIMITED applicability to valuation of LPBI Portfolio of Intellectual Property.

Our venture shares several industries, we have identified 12 economic segments where an acquirer can be identified. The content created using the methodology of curation of scientific findings with clinical interpretation by experts was developed in house to mitigate the information explosion in the Life Sciences and the information obsolescence. The content lands its attribution to electronic Scientific Publishing and to Pharmaceutical Media. Please review the business functions that this content could contribute to by the value drivers in each economic segment https://pharmaceuticalintelligence.com/2019-vista/opportunities-map-in-the-acquisition-arena/

Introduction to Three Intellectual Property Asset Classes of Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

http://pharmaceuticalintelligence.com

  •  LPBI Scientific Journal: 1.7Million eReaders, 5700 scientific articles [Pharmaceutics, Life Sciences, Medicine], 690 categories of research, 10,154Tags

https://lnkd.in/eEw5q7N

  • BioMed e-Series: 16 Volumes in Medicine and Life Sciences

https://lnkd.in/ekWGNqA

  •  e-Proceedings: Corpus of +70 Biotech & Medical Conferences, events covered in real time by a methodology developed in house yielding the e-Proceeding with one click at the end of the Conference.

https://lnkd.in/dc2qGAK

OTHER ASSETS

  • Asset Class IV is the platform, composition of methods and workflows for the content creation of scientific curations
  • Asset Class V is a Gallery of ~5000 images used in the articles and books
  • Asset Class VI is the Team of Experts.
  • Asset Class VII: Royalties on BioMed e-Series

Read Full Post »


Old Industrial Revolution Paradigm of Education Needs to End: How Scientific Curation Can Transform Education

Curator: Stephen J. Williams, PhD.

Dr. Cathy N. Davidson from Duke University gives a talk entitled: Now You See It.  Why the Future of Learning Demands a Paradigm Shift

In this talk, shown below, Dr. Davidson shows how our current education system has been designed for educating students for the industrial age type careers and skills needed for success in the Industrial Age and how this educational paradigm is failing to prepare students for the challenges they will face in their future careers.

Or as Dr. Davidson summarizes

Designing education not for your past but for their future

As the video is almost an hour I will summarize some of the main points below

PLEASE WATCH VIDEO

Summary of talk

Dr. Davidson starts the talk with a thesis: that Institutions tend to preserve the problems they were created to solve.

All the current work, teaching paradigms that we use today were created for the last information age (19th century)

Our job to to remake the institutions of education work for the future not the one we inherited

Four information ages or technologies that radically changed communication

  1. advent of writing: B.C. in ancient Mesopotamia allowed us to record and transfer knowledge and ideas
  2. movable type – first seen in 10th century China
  3. steam powered press – allowed books to be mass produced and available to the middle class.  First time middle class was able to have unlimited access to literature
  4. internet- ability to publish and share ideas worldwide

Interestingly, in the early phases of each of these information ages, the same four complaints about the new technology/methodology of disseminating information was heard

  • ruins memory
  • creates a distraction
  • ruins interpersonal dialogue and authority
  • reduces complexity of thought

She gives an example of Socrates who hated writing and frequently stated that writing ruins memory, creates a distraction, and worst commits ideas to what one writes down which could not be changed or altered and so destroys ‘free thinking’.

She discusses how our educational institutions are designed for the industrial age.

The need for collaborative (group) learning AND teaching

Designing education not for your past but for the future

In other words preparing students for THEIR future not your past and the future careers that do not exist today.

In the West we were all taught to answer silently and alone.  However in Japan, education is arranged in the han or group think utilizing the best talents of each member in the group.  In Japan you are arranged in such groups at an early age.  The concept is that each member of the group contributes their unique talent and skill for the betterment of the whole group.  The goal is to demonstrate that the group worked well together.

see https://educationinjapan.wordpress.com/education-system-in-japan-general/the-han-at-work-community-spirit-begins-in-elementary-school/ for a description of “in the han”

In the 19th century in institutions had to solve a problem: how to get people out of the farm and into the factory and/or out of the shop and into the firm

Takes a lot of regulation and institutionalization to convince people that independent thought is not the best way in the corporation

keywords for an industrial age

  • timeliness
  • attention to task
  • standards, standardization
  • hierarchy
  • specialization, expertise
  • metrics (measures, management)
  • two cultures: separating curriculum into STEM versus artistic tracts or dividing the world of science and world of art

This effort led to a concept used in scientific labor management derived from this old paradigm in education, an educational system controlled and success measured using

  • grades (A,B,C,D)
  • multiple choice tests

keywords for our age

  • workflow
  • multitasking attention
  • interactive process (Prototype, Feedback)
  • data mining
  • collaboration by difference

Can using a methodology such as scientific curation affect higher education to achieve this goal of teaching students to collaborate in an interactive process using data mining to create a new workflow for any given problem?  Can a methodology of scientific curation be able to affect such changes needed in academic departments to achieve the above goal?

This will be the subject of future curations tested using real-world in class examples.

However, it is important to first discern that scientific content curation takes material from Peer reviewed sources and other expert-vetted sources.  This is unique from other types of content curation in which take from varied sources, some of which are not expert-reviewed, vetted, or possibly ‘fake news’ or highly edited materials such as altered video and audio.  In this respect, the expert acts not only as curator but as referee.  In addition, collaboration is necessary and even compulsory for the methodology of scientific content curation, portending the curator not as the sole expert but revealing the CONTENT from experts as the main focus for learning and edification.

Other article of note on this subject in this Open Access Online Scientific Journal include:

The above articles will give a good background on this NEW Conceived Methodology of Scientific Curation and its Applicability in various areas such as Medical Publishing, and as discussed below Medical Education.

To understand the new paradigm in medical communication and the impact curative networks have or will play in this arena please read the following:

Scientific Curation Fostering Expert Networks and Open Innovation: Lessons from Clive Thompson and others

This article discusses a history of medical communication and how science and medical communication initially moved from discussions from select individuals to the current open accessible and cooperative structure using Web 2.0 as a platform.

 

Read Full Post »


In Data Science, A Pioneer Practitioner’s Portfolio of Algorithm-based Decision Support Systems for Operations Management in Several Industrial Verticals: Analytics Designer, Aviva Lev-Ari, PhD, RN

An overview of Data Science as a discipline is presented in

Data Science & Analytics: What do Data Scientists Do in 2020 and a Pioneer Practitioner’s Portfolio of Algorithm-based Decision Support Systems for Operations Management in Several Industrial Verticals

 

On this landscape about IT, The Internet, Analytics, Statistics, Big Data, Data Science and Artificial Intelligence, I am to tell stories on my own pioneering work in data science, Algorithm-based decision support systems design for different organizations in several sectors of the US economy:

Images on 12/7/2019

  • Startups:
  1. TimeØ Group – The leader in Digital Marketplaces Design
  2. Concept Five Technologies, Inc. – Commercialization of DoD funded technologies
  3. MDSS, Inc. – SAAS in Analytical Services
  4. LPBI Group – Pharmaceutical & Media
  • Top Tier Management Consulting: SRI International, Monitor Group;
  • OEM: Amdahl Corporation;
  • Top 6th System Integrator: Perot System Corporation;
  • FFRDC: MITRE Corporation.
  • Publishing industry: was Director of Research at McGraw-Hill/CTB.
  • Northeastern University, Researcher on Cardiovascular Pharmacotherapy at Bouve College of Health Sciences (Independent research guided by Professor of Pharmacology)

Type of institutions:

  • For-Profit corporations: Amdahl Corp, PSC, McGraw-Hill
  • For-Profit Top Tier Consulting: Monitor Company, Now Deloitte
  • Not-for-Profit Top Tier Consulting: SRI International
  • FFRDC: MITRE
  • Pharmaceutical & Media Start up in eScientific Publishing: LPBI Group:
  1. Developers of Curation methodology for e-Articles [N = 5,700],
  2. Developers of electronic Table of Contents for e-Books in Medicine [N = 16, https://lnkd.in/ekWGNqA] and
  3. Developers of Methodologies for real time press coverage and production of e-Proceedings of Biotech Conferences [N = 70].

 

Autobiographical Annotations: Tribute to My Professors

 

Pioneering implementations of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI MA’76

https://pharmaceuticalintelligence.com/2018/05/28/pioneering-implementations-of-analytics-to-business-decision-making-contributions-to-domain-knowledge-conceptualization-research-design-methodology-development-data-modeling-and-statistical-data-a/

Recollections of Years at UC, Berkeley, Part 1 and Part 2

  • Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other professors and other peers

https://pharmaceuticalintelligence.com/2018/03/15/recollections-my-days-at-berkeley-9-1978-12-1983-about-my-doctoral-advisor-allan-pred-other-professors-and-other-peer/

  • Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83

https://pharmaceuticalintelligence.com/2018/05/24/recollections-part-2-while-rolling-is-preceded-by-while-enrolling-autobiographical-alumna-recollections-of-berkeley-aviva-lev-ari-phd83/

Accomplishments

The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation

For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets

Thriving at the Survival Calls during Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL

Professional Self Re-Invention: From Academia to Industry – Opportunities for PhDs in the Business Sector of the Economy

Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RNMarch 2018

Was prepared for publication in American Friends of the Hebrew University (AFHU), May 2018 Newsletter, Hebrew University’s HUJI Alumni Spotlight Section.

Aviva Lev-Ari’s profile was up on 5/3/2018 on AFHU website under the Alumni Spotlight at https://www.afhu.org/

On 5/11/2018, Excerpts were Published in AFHU e-news.

https://us10.campaign-archive.com/?u=5c25136c60d4dfc4d3bb36eee&id=757c5c3aae&e=d09d2b8d72

https://www.afhu.org/2018/05/03/aviva-lev-ari/

 

Read Full Post »


Tweets and Retweets by @pharma_BI and @AVIVA1950 for #NEVS at 2019 New England Venture Summit, December 4, 2019 at the Hilton in Boston, Dedham, MA, hosted by youngStartUp #NEVS

 

Event Agenda

https://pharmaceuticalintelligence.com/2019/07/23/2019-new-england-venture-summit-december-4th-2019-at-the-hilton-in-boston-dedham-ma-hosted-by-youngstartup-nevs/

liked your Tweet

#NEVS19 @pharma_BI @AVIVA1950 #AI strategic investment high tech ventures are long term for VC and founders milestones entrepreneurs need to meet for BC To accept valuation board controlled by Entrepreneur or by VCs convertible 15% discount negotiation power at product stage vary pic.twitter.com/WxNuRMGn8l

liked your Tweet

We are in the Cloud only #NEVS19 @AVIVA1950 @pharma_BI twitter.com/stevesherlock/

liked your Tweet

#NEVS19 #pharma_BI @AVIVA1950 Mediktor is SAAS B2B in 12 languages need $5-$15M access to Health Care pic.twitter.com/RadPqiAZj6

liked 18 of your Tweets

#NEVS19 @pharma_BI @AVIVA1950 Asymmetrex stem cell counter service model need to establish cell culture lab improve SW automation establish ASTM standard achieve FDA guidance pic.twitter.com/z14Yes3tL9

Show all

liked your Tweet

#NEVS19 @pharma_BI @AVIVA1950 #VC #Investors are presenting the #pulse #investment #market #institutionalInvestors #Ecits #IPO by #M&A #women #leaders #platform #investment #corporate #technology #gamechanging #Entrepreneur #raisingfunds 12-18 month #economic #downturn #deals pic.twitter.com/fFdOQphhsd

Aviva Lev-Ari
@AVIVA1950

Great panel over 120 years of #investment #experience guiding young #entrepreneurs #NEVS19@pharma_BI

Quote Tweet
Gayatri Sarkar 

🌴

🌏

⌛️

@GS_VCactivist
·
I had such a great time talking about “Art of Negotiating Termsheets” with @XFactorVentures @AMD ventures @goodaicapital Millenium Technology Value Partner and @NexusVP at #NEVS19

Image

Image

Image

Aviva Lev-Ari
@AVIVA1950

#NEVS19

who are the customers vs focus on technology and products great technology can fail because management is not aligned technologies can not get traction due to slow adoption in the market optimized valuation take partners long term cost structure

Image

James L. Sherley
@asymmetrex

Asymmetrex at the New England Venture Summit today in Boston(#NEVS19). A featured Life Sciences presenter for stem cell counting.
James L. Sherley, M.D., Ph.D. on LinkedIn: #NEVS19
Asymmetrex at the New England Venture Summit today in Boston(#NEVS19). A featured Life Sciences presenter for stem cell counting….
linkedin.com
1
2

Vivonics Inc.
@VivonicsInc

Vivonics / CranioSense CEO Gordon Hirschman at the #NEVS19 New England Venture Summit, seeking investment for IPASS, our medical device for non-invasive assessment of intracranial pressure (ICP), critical in traumatic brain injury (TBI), stroke and other brain conditions.

Image

1
3

Medigate
@MedigateLtd

Jonathan Langer, CEO of

, spoke with

to share his predictions for #IoT trends in 2020. Read the article here: tek.io/35zIUiC. #cybersecurity

Image

1
10
18

Aviva Lev-Ari
@AVIVA1950

#NEVS19

#AI strategic investment high tech ventures are long term for VC and founders milestones entrepreneurs need to meet for BC To accept valuation board controlled by Entrepreneur or by VCs convertible 15% discount negotiation power at product stage vary

Image

1
2

Aviva Lev-Ari
@AVIVA1950

#NEVS19

spin off @BOSTONUniversity microscopy based ExoBiew #exsosome cell communication Luminex is competitor companion diagnostics liquid Biopsy pancreatic cancer @ BIDMC interrogate exosome for therapeutics another exosome sold for $330M

Image

Aviva Lev-Ari
@AVIVA1950

Quote Tweet
Steve Sherlock
@SteveSherlock
·
Session on angel investing, interesting insights e.g. be transparent! #nevs19 #startups #pitchdeck

Image

Aviva Lev-Ari
@AVIVA1950

#NEVS19

who are the customers vs focus on technology and products great technology can fail because management is not aligned technologies can not get traction due to slow adoption in the market optimized valuation take partners long term cost structure

Image

Aviva Lev-Ari
@AVIVA1950

#NEVS19

SIG.NUM SIG.RHYTHM SIG.12-LED #ECG alternative technology to 12 leads a pad with sensors

Image

Aviva Lev-Ari
@AVIVA1950

#NEVS19

spin off @BOSTONUniversity microscopy based ExoBiew #exsosome cell communication Luminex is competitor companion diagnostics liquid Biopsy pancreatic cancer @ BIDMC interrogate exosome for therapeutics another exosome sold for $330M

Image

1
1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

@ABIVA1950

MICROSCOPY INDUSTRY Microdissection market life science research platform open platform for Re-agent companies Cartridge removable Live Cell imaging market need $5M

Image

1
1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

micro needles for diagnostics using ISF #Interstitial System Fluid uses #glucose, #allergy, #neonatal

Image

Aviva Lev-Ari
@AVIVA1950

#NEVS19

Asymmetrex stem cell counter service model need to establish cell culture lab improve SW automation establish ASTM standard achieve FDA guidance

Image

1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

FIRST LIGHT DIAGNOSTICS antibiotics resistance C-Diff MRSA Rapid AST Anti microbial susceptibility Testing B Round pre Revenue small valuation

Image

1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

A DOWN TURN HURTS MOST INVESTORS FUND RAISERS don’t go for the biggest valuation if not meet numbers second trench negatively affected same for valuation technology progresses support Series A, B

1

1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

device requires less energy than LVAD no support continuous mode pulsitile mode Euro16M needed to complete animal trials

Image

1

Aviva Lev-Ari

Aviva Lev-Ari
@AVIVA1950

Quote Tweet
Steve Sherlock
@SteveSherlock
·
Quote “I never invest in part time founders” and “If you can’t commit full time you shouldn’t be raising money” #startups #vc #angel #nevs19

Aviva Lev-Ari
@AVIVA1950

#NEVS19

micro needles for diagnostics using ISF #Interstitial System Fluid uses #glucose, #allergy, #neonatal

Image

1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

device requires less energy than LVAD no support continuous mode pulsitile mode Euro16M needed to complete animal trials

Image

1

Aviva Lev-Ari
@AVIVA1950

Quote Tweet
Steve Sherlock
@SteveSherlock
·
Quote “I never invest in part time founders” and “If you can’t commit full time you shouldn’t be raising money” #startups #vc #angel #nevs19

Aviva Lev-Ari
@AVIVA1950

#NEVS19

A DOWN TURN HURTS MOST INVESTORS FUND RAISERS don’t go for the biggest valuation if not meet numbers second trench negatively affected same for valuation technology progresses support Series A, B

1

Aviva Lev-Ari
@AVIVA1950

Image

2

Aviva Lev-Ari
@AVIVA1950

#NEVS19

A DOWN TURN HURTS MOST INVESTORS FUND RAISERS don’t go for the biggest valuation if not meet numbers second trench negatively affected same for valuation technology progresses support Series A, B

1

Aviva Lev-Ari
@AVIVA1950

#NEVS19

SIG.NUM SIG.RHYTHM SIG.12-LED #ECG alternative technology to 12 leads a pad with sensors

Image

Read Full Post »

Older Posts »